Unique ID issued by UMIN | UMIN000001500 |
---|---|
Receipt number | R000001568 |
Scientific Title | A phase II study of percutaneous osteoplasty for painful malignant bone tumor (JIVROSG-0703) |
Date of disclosure of the study information | 2008/11/12 |
Last modified on | 2011/05/14 15:14:23 |
A phase II study of percutaneous osteoplasty for painful malignant bone tumor (JIVROSG-0703)
Percutaneous osteoplasty for bone tumor.
A phase II study of percutaneous osteoplasty for painful malignant bone tumor (JIVROSG-0703)
Percutaneous osteoplasty for bone tumor.
Japan |
Malignant vertebral and pelvic bone tumor
Orthopedics | Radiology | Anesthesiology |
Malignancy
NO
To evaluate the clinical efficacy, safety, and QOL of percutaneous osteoplasty in patients with malignant bone tumors.
Safety,Efficacy
Confirmatory
Explanatory
Phase II
Clinical efficacy
Adverse events and QOL
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment | Maneuver |
Under local anesthesia and fluoroscopic or CT guidance, a needle is percutaneously inserted into the malignant bone tumor and the cement is injected.
20 | years-old | <= |
Not applicable |
Male and Female
1) Primary or metastatic malignant tumor in thoracic or lumber vertebral or pelvic bone tumor.
2) Severe pain adversely influencing on QOL.
3) Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions.
4) Age =>20
5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3.
6) Expected survival more than 4 weeks.
7) Written informed consent.
1) Cardiac failure requiring medication.
2) Vertebral tumor with destruction of the posterior part of vertebral body or compression of spinal cord.
3) Require the treatment of more than 4 vertebral bodies at single session.
4) Destruction of the bone cortex of aceatabulum.
5) No severe pain (less than 2 of VAS).
6) Uncontrolled bleeding tendency.
7) Severe drug allergy.
8) Comorbid infectious disease.
9) Active inflammatory process in the target lesion.
10) Radiation therapy for the target lesion.
11) Within 4 weeks after the completion of radiation therapy with a treatment response.
12) Unable to keep prone position for 1 hour.
13) Pregnancy.
33
1st name | |
Middle name | |
Last name | Osamu Matsui |
Kanazawa University Graduate School of Medicine
Department of Radiology
13-1, Takaramachi, Kanazawa 920-8641, Japan
076-265-2323
1st name | |
Middle name | |
Last name | Yasuaki Arai |
JIVROSG, Coordinating Office
Division of Diagnostic Radiology, National Cancer Center Hospital
5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan
03-3542-2511
http://jivrosg.umin.jp/
Japan Interventional Radiology in Oncology Study Group (JIVROSG)
Ministry of Health, Labour and Welfare
Japan
NO
2008 | Year | 11 | Month | 12 | Day |
http://jivrosg.umin.jp
Unpublished
Completed
2008 | Year | 02 | Month | 29 | Day |
2008 | Year | 04 | Month | 01 | Day |
2011 | Year | 04 | Month | 01 | Day |
2011 | Year | 06 | Month | 01 | Day |
2011 | Year | 07 | Month | 01 | Day |
2011 | Year | 10 | Month | 01 | Day |
2008 | Year | 11 | Month | 12 | Day |
2011 | Year | 05 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001568